jobberone
Kane Ala
- Messages
- 54,219
- Reaction score
- 19,659
http://stm.sciencemag.org/content/5/177/177ra37
Ok, the following is an abstract from a journal and I don't expect all to read but the take home message here could be very important for mankind. Malaria remains a huge problem for the world killing and causing debilitating illness for millions and millions each year. Two to three thousand deaths occur every day primarily children in Africa.
If this works out well then we'll have a new medicine that treats all phases of the disease. The meds we have now can create a lot of problems esp those for prevention. Here's the wiki link for malaria: http://en.wikipedia.org/wiki/Malaria
The goal for developing new antimalarial drugs is to find a molecule that can target multiple stages of the parasite’s life cycle, thus impacting prevention, treatment, and transmission of the disease. The 4(1H)-quinolone-3-diarylethers are selective potent inhibitors of the parasite’s mitochondrial cytochrome bc1 complex. These compounds are highly active against the human malaria parasites Plasmodium falciparum and Plasmodium vivax. They target both the liver and blood stages of the parasite as well as the forms that are crucial for disease transmission, that is, the gametocytes, the zygote, the ookinete, and the oocyst. Selected as a preclinical candidate, ELQ-300 has good oral bioavailability at efficacious doses in mice, is metabolically stable, and is highly active in blocking transmission in rodent models of malaria. Given its predicted low dose in patients and its predicted long half-life, ELQ-300 has potential as a new drug for the treatment, prevention, and, ultimately, eradication of human malaria.
Ok, the following is an abstract from a journal and I don't expect all to read but the take home message here could be very important for mankind. Malaria remains a huge problem for the world killing and causing debilitating illness for millions and millions each year. Two to three thousand deaths occur every day primarily children in Africa.
If this works out well then we'll have a new medicine that treats all phases of the disease. The meds we have now can create a lot of problems esp those for prevention. Here's the wiki link for malaria: http://en.wikipedia.org/wiki/Malaria
The goal for developing new antimalarial drugs is to find a molecule that can target multiple stages of the parasite’s life cycle, thus impacting prevention, treatment, and transmission of the disease. The 4(1H)-quinolone-3-diarylethers are selective potent inhibitors of the parasite’s mitochondrial cytochrome bc1 complex. These compounds are highly active against the human malaria parasites Plasmodium falciparum and Plasmodium vivax. They target both the liver and blood stages of the parasite as well as the forms that are crucial for disease transmission, that is, the gametocytes, the zygote, the ookinete, and the oocyst. Selected as a preclinical candidate, ELQ-300 has good oral bioavailability at efficacious doses in mice, is metabolically stable, and is highly active in blocking transmission in rodent models of malaria. Given its predicted low dose in patients and its predicted long half-life, ELQ-300 has potential as a new drug for the treatment, prevention, and, ultimately, eradication of human malaria.
